Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this project is to determine if a new combination of drugs, erlotinib
(Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian
cancer whose cancer has progressed while on prior standard chemotherapy treatment with a
taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).